News

FDA Approves Nucala for Chronic Obstructive Pulmonary Disease
By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
pharmaphorum4d
GSK claims first approval for Nucala in COPD
While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...
Daily Jang2d
Nucala receives FDA approval for COPD
The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...
Fierce Pharma5d
GSK revs up launch plans after Nucala's FDA approval in COPD, targeting £500M opportunity
The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...
GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
GlobalData on MSN4d
FDA approves GSK’s Nucala to treat COPD
GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...
BioSpace4d
GSK Wins COPD Expansion for Nucala After FDA Delay
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
PharmExec4d
FDA Approves GSK’s Nucala for Chronic Obstructive Pulmonary Disease
Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...
The Pharma Letter4d
Nucala approved by FDA for use in adults with COPD
UK pharma major GSK (LSE: GSK) yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala ...
GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment
GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...
Pharmaceutical Technology8d
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...
MPR4d
FDA Approves Nucala for COPD With an Eosinophilic Phenotype
The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...